AMENDMENT TO THE SPECIFICATION

On page 2, line 8 of the specification replace the background of the invention with following:

This application is a continuation of patent application, Serial No. 09/662,270, filed on September 14, 2000, now abandoned, which is a divisional application of U.S. Serial No. 09/097,199, filed on June 12, 1998 and issued as U.S. Patent 6,218,529 which was a continuation–in–part of U.S. Patent Application Serial No. 08/692,787 filed July 31, 1996 and issued as U.S. Pat. No. 5,882,864, which claims the benefit of U.S. provisional applications 60/001,655, filed Jul. 31, 1995, and 60/013,611, filed Jan. 11, 1996, both now abandoned. The entire text of the above-referenced disclosure is specifically incorporated by reference herein without disclaimer.

Please replace the paragraph beginning on line 15 of page 31, with the following amended paragraph:

Both cDNA and genomic sequences are suitable for eukaryotic expression, as the host cell will generally process the genomic transcripts to yield functional mRNA for translation into protein. In addition, it is possible to use partial sequences for generation of antibodies against discrete portions of a gene product, even when the entire sequence of that gene product remains unknown. Computer programs are available to aid in the selection of regions which have potential immunologic significance. For example, software capable of carrying out this analysis is readily available commercially from MacVector ™ (IBI, New Haven, CT). The software typically uses standard algorithms such as the Kyte/Doolittle or Hopp/Woods methods for locating hydrophilic sequences which are characteristically found on the surface of proteins and are, therefore, likely to act as antigenic determinants.

Please replace the paragraph beginning on line 20 of page 51, with the following amended paragraph:

To provide a detecting means, the second or third antibody will have an associated label to allow detection. Preferably, this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact and incubate the first or second immunecomplex with a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immunecomplex formation (e.g., incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween™).

Please replace the paragraph beginning on line 15 of page 87, with the following amended paragraph:

Differentially appearing PCR products, that might represent differentially expressed genes, were excised from the gel with a razor blade, purified from the agarose using the Geneclean™ kit (Bio 101, Inc.), eluted in water and cloned directly into plasmid vectors using the TA cloning strategy (Invitrogen, Inc., and Promega, Inc.). These products were not reamplified after the initial PCR fingerprinting protocol.

Please replace the paragraph beginning on line 6 of page 117, with the following amended paragraph:

A first generation polyclonal antibody has been produced in rabbits using a KLH conjugated synthetic peptide (21 amino acids). The peptide, of sequence listed below, was chosen for antigenicity by a computer software program (DNASTAR™, Madison, WI).

Please replace the paragraph beginning on line 19 of page 117, with the following amended paragraph:

Computer analyses using bioinfomatics from public databases (MotifFinder program in the GenomeNet database, Japan, motif@genome.ad.jp) indicate that the UC 28 peptide has a

possible 26 amino acid transmembrane domain from amino acid 34 to amino acid 50, and also contains three PKC phosphorylation sites beginning at amino acids 62 (SQK), 89 (TMK), and 94 (SMK) and one myristylation site beginning at amino acid 118 (GLECCL) (SEQ ID NO:88). *In vitro* translation studies using rabbit reticulocyte lysate methods were performed to evaluate the size of the translated product from the open reading frame. A single 17 kDa protein product was obtained, which is the correct predicted size from the open reading frame.

Please replace the paragraph beginning on line 8 of page 119, with the following amended paragraph:

American Cancer Society-Facts and Figures-1998, ~~http://~~www.cancer.org/statistics/98cff/98prosta.html.

Please delete the sequence listing at pages 126-162 and renumber subsequent pages accordingly.

Please add the substitute Sequence Listing numbered pages 1-34 attached hereto as Appendix A, immediately following the Abstract.